logo-loader
RNS
Haleon PLC

Haleon PLC - Director/PDMR Shareholding

RNS Number : 8469K
Haleon PLC
02 July 2026
 

Icon Description automatically generated

 

Haleon plc: Director/PDMR Shareholding 

 

2 July 2026: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by a Person Discharging Managerial Responsibilities ("PDMR").

 

This notification sets out the details of the vesting of a Haleon share award over ordinary shares made to a PDMR in October 2024 under the Haleon Performance Share Plan and the subsequent sale of ordinary shares to meet tax liabilities.

 

On 30 June 2026, Dawn Allen, Chief Financial Officer, received the vesting of an award of Haleon ordinary shares under the Haleon Performance Share Plan. Vesting included dividends accrued.

The award under the Performance Share Plan was conditional on continued employment and on the satisfaction of the performance conditions over the performance period ended on 31 December 2025 approved by the Remuneration Committee, which (after tax on the gross award) must be retained until the shareholding requirement is met, and in any event for Executive Directors two years after receipt.

Performance targets and levels of achievement are disclosed in the 2025 Annual Report and 20-F. The award is subject to malus and clawback provisions.

 

 

Details of the issuer or emission allowance market participant

 

a)  

 

Name of the entity 

 

Haleon plc 

b)  

 

LEI  

 

549300PSB3WWEODCUP19 

 

 

Reason for the notification  

 

a)  

 

Position/status  

 

 

Chief Financial Officer

b)  

 

Initial notification /Amendment to prior notifications

 

Initial Notification 

 

 

Details of the person discharging managerial responsibilities / person closely associated ("PCA")

a)

PDMR/PCA

PDMR

 

b)  

 

Name 

 

Dawn Allen

 

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  

 

a)  

 

Description of Instrument  

Share

 



Identification code  

GB00BMX86B70

 



b)  

 

Nature of the transaction  

 

 

Acquisition of Ordinary Shares in respect of the Haleon plc Performance Share Plan (Buyout award).

 

c)  

 

Currency, Price(s) and Volume(s)  








Price(s) 

Volume(s) 





Nil

283,193.151771







d)  

 

Aggregated information  




- Aggregated volume 

N/A



- Price 




e)  

 

Date of the transaction  

 

30 June 2026

f)  

 

Place of the transaction  

 

Outside a trading venue

 

 

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  

 

a)  

 

Description of Instrument  

Share

 



Identification code  

GB00BMX86B70

 



b)  

 

Nature of the transaction  

 

 

Automatic disposal of Ordinary Shares resulting from Haleon plc Performance Share Plan (Buyout Award) vesting to cover tax liabilities.

 

c)  

 

Currency, Price(s) and Volume(s)  








Price(s) 

Volume(s) 





£3.523867

133,300.732432







d)  

 

Aggregated information  




- Aggregated volume 

N/A



- Price 




e)  

 

Date of the transaction  

 

30 June 2026

f)  

 

Place of the transaction  

 

London Stock Exchange (XLON) 

 

 

 

Amanda Mellor

Company Secretary

 

About Haleon

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion consumers and are recommended by health professionals around the world.

 

For more information, please visit www.haleon.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBXGDRIBGDGLD
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read